atsReferences = `
AstraZeneca Pharmaceuticals LP. Development Pipeline as of December 31, 2015. AstraZeneca website. http://www.astrazeneca.com/our-science/pipeline.html. Accessed April 15, 2016.

Barnes P J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. <em>J Allergy Clin Immunol.</em> 2013;131(3):637.

Barnes P J. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. <em>Eur Respir J</em>. 2002;19:183-184.

Cazzola M, Lopez-Campos J, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. <em>Eur Respir J</em>. 2013;42: 885-886.

De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor Modulators. <em>Curr Opin Pharmacol</em>. 2010;10(4):498,502.

Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D. Increased phosphorylated p38 mitogenactivated protein kinase in COPD lungs. <em>Eur Respir J</em>. 2013; 42:32.

Gauvreau G M, O’Byrne P M, Boulet L, et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. <em>N Engl J Med</em>. 2014;370(22):2103.

Ghazi A, Trikha A, Calhoun W J. Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. <em>Expert Opin Biol Ther</em>. 2012:2.

Krieg A M. Therapeutic potential of Toll-like receptor 9 activation. <em>Nature Rev Drug Discov</em>. 2006;5:447.

Laine D I, Busch-Petersen J. Inhibitors of cathepsin C (dipeptidyl peptidase I). <em>Expert Opin Ther Pat</em>. 2010;10(4):498.

Mardh C K, Gustavsson M, Smailagic A. Pharmacological Characterization Of Azd5423, An Inhaled Non-Steroidal Agonist Of The Glucocortiocoid Receptor. <em>Am J Respir Crit Care Med</em>. 2015;191:A5656.

Molfino N A, Gossage D, Kolbeck R, Parker J M, Geba G P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. <em>Clin Exp Allergy</em>. 2011;42:278.

NIH U.S. National Library of Medicine TOXNET. Substance Name: Tezepelumab [USAN]. NIH U.S.<br>

Noppert S J, Fitzgerald K A, Hertzog P J. The role of type I interferons in TLR responses.<em>Immunol Cell Biol</em>. 2007;85:446-448,450.

Pearl Therapeutics Inc. LAMA/LABA/ICS Triple Combination. Pearl website. https://www.pearltherapeutics.com/pipeline-overview. Accessed 2015.
Pelaia G, Maselli R, Gallelli L. Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. <em>Multidiscip Respir Med</em>. 2014;9(64):2. 

Pelaia G, Renda T, Gallelli L, et al. Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma. <em>Respir Med</em>. 2008;102:1175.

Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. <em>Nature Rev Drug Discov</em>. 2012;11:966.

Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. <em>Eur Respir J</em>. 2013;41:330,335. 

Rhen T, Cidlowski J A. Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs. <em>N Engl J Med</em>. 2005;353(16):1712.

Sundahl N, Bridelance J, Libert C, De Bosscher K, Beck I M. Selective glucocorticoid receptor modulation: New directions with non-steroidal scaffolds. <em>Pharmacol Ther</em>. 2015;152:29.

Venkayya R, Lam M, Willkom M, Grünig G, Corry D B, Erle D J. The Th2 Lymphocyte Products IL-4 and IL-13 Rapidly Induce Airway Hyp erresponsiveness Through Direct Effects on Resident Airway Cells. <em>Am J Resir Cell Mol Biol</em>. 2002;26:202,207.

Yang Y, Kim S C, Yu T., et al. Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses. <em>Mediators Inflamm</em>. 2014;2014:2-3.
`
